| 摘要 |
The present invention encompasses the use of a CD2 antagonist, preferably ME DI- 507, an analog, derivative or an antigen-binding fragment thereof as a singl e agent therapy for the prevention, treatment, management, or amelioration of cancer, particularly a T-cell malignancy, or one or more symptoms thereof. T he present invention also encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative of an antigen-binding fragment thereof in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising a CD2 antagonist, preferably MEDI-507 , an analog, derivative or an antigen-binding fragment thereof in amounts effective to prevent, treat, manage, or ameliorate cancer, particularly a T- cell malignancy, or one or more symptoms thereof.
|
